![]() PF-05231023 structure
|
Common Name | PF-05231023 | ||
---|---|---|---|---|
CAS Number | 1037589-69-7 | Molecular Weight | 528.55 | |
Density | N/A | Boiling Point | N/A | |
Molecular Formula | C26H32N4O8 | Melting Point | N/A | |
MSDS | N/A | Flash Point | N/A |
Use of PF-05231023PF-05231023, a long-acting fibroblast growth factor 21 (FGF21) analog, is a FGF21-receptor agonist, suitable for development as a potential treatment for T2DM[1][5]. |
Name | PF-05231023 |
---|
Description | PF-05231023, a long-acting fibroblast growth factor 21 (FGF21) analog, is a FGF21-receptor agonist, suitable for development as a potential treatment for T2DM[1][5]. |
---|---|
Related Catalog | |
Target |
FGF21-receptor[5]. |
In Vitro | PF-05231023 is a long-acting fibroblast growth factor 21 (FGF21) analog[2]. |
In Vivo | Administration of native FGF21 and PF-05231023 ( 3 mg/kg or 10 mg/kg ) improves glucose tolerance and liver insulin sensitivity in Zucker rats[3]. PF-05231023 (10 mg/kg) shows protective effects on Akita retinas. PF-05231023 (10 mg/kg) decreases retinal inflammation in diabetic mice. PF-05231023 (10 mg/kg) administration reduces retinal IL-1β mRNA expression in Akita mice. PF-05231023 (10 mg/kg) administration increases cone-specific arrestin4 expression in Akita mice. PF-05231023 (10 mg/kg) administration restores photoreceptor morphology in Akita mice. PF-05231023 (10 mg/kg) inhibits oxidative-stress-induced inflammation in photoreceptors. PF-05231023 (10 mg/kg) administration decreases the variability of retinal NRF2 levels and shows a trend (non-significant) towards increased NRF2 levels in Akita mice[4]. |
References |
Molecular Formula | C26H32N4O8 |
---|---|
Molecular Weight | 528.55 |
Storage condition | 2-8℃ |